A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Inclusion:
Documented diagnosis of multiple myeloma (MM) as defined by the criteria below:
Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD)38 antibody
Documented evidence of progressive disease (PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by IMWG criteria
Toxicity related to previous anticancer therapy must have resolved to Grade 1 or better
Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the start of study treatment administration
Exclusion:
Participate-In-This-Study1@its.jnj.com844-434-4210
Irvine, California 92618, United States
Toronto, Ontario M5G 2M9, Canada
Montreal, Quebec H1T 2M4, Canada
Ramat Poriya, 1520800, Israel
Bunkyō City, 113 8677, Japan
Kamakura-shi, 247-8533, Japan
Lorenskog, 1478, Norway